Table 3.
Standardized incidence ratios of secondary malignancy in patients diagnosed with primary thyroid cancer, stratified by follow-up intervals after diagnosis of primary malignancy. Bold typeface indicates p<0.05.
| Time after diagnosis of primary malignancy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2–11 months | 12–59 months | 60–119 months | ≥120 months | Total | ||||||
| Obs/Exp | SIR (95% CI) | Obs/Exp | SIR (95% CI) | Obs/Exp | SIR (95% CI) | Obs/Exp | SIR (95% CI) | Obs/Exp | SIR (95% CI) | |
| Prostate | 20/12 | 1.64 (1–2.5) | 70/49 | 1.42 (1.1–1.8) | 47/38 | 1.25 (0.9–1.7) | 7/13 | 0.52 (0.2–1.1) | 144/113 | 1.28 (1.1–1.5) |
| Urinary Bladder | 4/2 | 1.75 (0.5–4.5) | 8/10 | 0.84 (0.4–1.7) | 5/8 | 0.65 (0.2–1.5) | 2/3 | 0.69 (0.1–2.5) | 19/22 | 0.84 (0.5–1.3) |
| Kidney | 2/1 | 1.59 (0.2–5.8) | 8/5 | 1.57 (0.7–3.1) | 18/4 | 4.49 (2.7–7.1) | 2/1.5 | 1.36 (0.2–4.9) | 30/12 | 2.53 (1.7–3.6) |
| Colorectal | 2/4 | 0.55 (0.1–2.0) | 19/15 | 1.29 (0.8–2.0) | 3/11 | 0.27 (0.1–0.8) | 5/3.9 | 1.28 (0.4–3.0) | 29/33 | 0.87 (0.6–1.3) |
| Lung and Bronchus | 3/5 | 0.62 (0.1–1.8) | 18/19 | 0.93 (0.6–1.5) | 15/15 | 1.01 (0.6–1.7) | 4/5 | 0.75 (0.2–1.9) | 40/44 | 0.9 (0.6–1.2) |
| Esophagus | 2/0.5 | 3.71 (0.5–13) | 0/2 | 0 (0–1.7) | 3/2 | 1.76 (0.4–5.2) | 0/0.6 | 0 (0–6.0) | 5/5.1 | 0.99 (0.3–2.3) |
| Pancreas | 2/0.9 | 2.3 (0.3–8) | 2/4 | 0.55 (0–2) | 5/3 | 1.73 (0.6–4.0) | 2/1 | 1.84 (0.2–6.6) | 11/8.5 | 1.3 (0.7–2.3) |
| Hodgkin’s Lymphoma | 1/0.16 | 6.18 (0.2–34) | 0/0.6 | 0 (0–6) | 0/0.4 | 0 (0–9) | 0/0.1 | 0 (0–28) | 1/1.3 | 0.77 (0–4.3) |
| Non-Hodgkin’s Lymphoma | 4/1.6 | 2.48 (0.7–6.4) | 13/7 | 2.00 (1.0–3.4) | 6/5 | 1.2 (0.4–2.6) | 1/1.8 | 0.55 (0.0–3.1) | 24/14.9 | 1.61 (1.0–2.4) |
| Leukemia | 0/0.99 | 0 (0–3.7) | 9/4 | 2.21 (1.0–4.2) | 4/3 | 1.26 (0.3–3.2) | 1/1.2 | 0.86 (0.0–4.8) | 14/9 | 1.49 (0.8–2.5) |